Taysha Gene Therapies, Inc. Accrued Liabilities and Other Liabilities
Taysha Gene Therapies, Inc. (TSHA) had Accrued Liabilities and Other Liabilities of $16.81 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities and Other Liabilities $16.81M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $15.53M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $20.28M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $17.71M.
| Period end | Accrued Liabilities and Other Liabilities |
|---|---|
| 2026-06-30 | $16.81M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $15.53M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $20.28M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $17.71M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $12.15M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $10.76M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $12.86M 10-K · filed 2026-03-19 |
| 2024-09-30 | $12.61M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $11.88M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $13.56M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $12.28M 10-K · filed 2025-02-26 |
| 2023-09-30 | $13.64M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $19.63M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $16.60M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.29M 10-K · filed 2024-03-19 |
| 2022-09-30 | $17.89M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $18.99M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $26.62M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $29.98M 10-K · filed 2023-03-28 |
| 2021-09-30 | $21.16M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $22.04M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $14.88M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $5.13M 10-K · filed 2022-03-31 |
| 2019-12-31 | $150.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |